Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 02 11 2020
revised: 06 02 2021
accepted: 15 02 2021
pubmed: 6 3 2021
medline: 14 5 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

One of the most prominent and concerning complications associated with coronavirus disease 2019 (COVID-19) is venous and arterial thromboembolisms. The aim of the present study was to delineate the prevalence of thromboembolic events and the current status of prophylactic anticoagulation therapy in patients with COVID-19 in Japan. Between February 1 and August 31, 2020, we performed a dual-center, retrospective cohort study based on data obtained from the medical charts of COVID-19 patients admitted to healthcare facilities in Japan. The primary outcome was any thromboembolic event including pulmonary embolism (PE), deep vein thrombosis (DVT), myocardial infarction, ischemic stroke and other systemic thromboemboli. During the study period, we extracted 628 consecutive patients admitted for COVID-19. Prophylactic anticoagulant therapy was administered in 63 (10%) patients of whom 20 (31.7%) were admitted to the intensive care unit (ICU). Thromboembolic events occurred in 18 (2.9%) patients (14.3% of patients in ICU and 2.2% of patients in the general wards). DVT were detected in 13 (2.1%) patients, PE in 11 (1.8%), and both DVT and PE in 6 (0.96%) patients. An increasing prevalence in thromboembolic events was noted with progressive clinical severity. Overall in-hospital mortality was 4.8%. Prophylactic anticoagulation therapy was administered in only 10% of all hospitalized COVID-19 patients. The prevalence of any thromboembolic events was 2.9% in COVID-19 patients with most events occurring in severe and critical patients. Therefore, prophylactic anticoagulation therapy may be warranted in severe and critical patients but in asymptomatic to moderate patients the practice remains controversial.

Identifiants

pubmed: 33663933
pii: S1341-321X(21)00059-3
doi: 10.1016/j.jiac.2021.02.019
pmc: PMC7894095
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-875

Informations de copyright

Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None declared.

Auteurs

Sho Fujiwara (S)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: fujiwarackn@gmail.com.

Mikio Nakajima (M)

Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan; Department of Trauma and Critical Care Medicine, Kyorin University School of Medicine, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: mikioh@ks.kyorin-u.ac.jp.

Richard H Kaszynski (RH)

Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: fbi007x@hotmail.com.

Kazuaki Fukushima (K)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: fukushima-ngi@umin.ac.jp.

Masaru Tanaka (M)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: masaru18750302@gmail.com.

Keishiro Yajima (K)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: keishiroyajima@gmail.com.

Taiichiro Kobayashi (T)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: tkobayashi@cick.jp.

Noritaka Sekiya (N)

Department of Infection Prevention and Control, Department of Clinical Laboratory, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: qnmnk410@ybb.ne.jp.

Yasuhiro Yamamoto (Y)

Department of Pediatrics, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: yamamoto@medicalmac.com.

Maki Miwa (M)

Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: cucumber_cetriolo@nifty.com.

Ayaka Ishihata (A)

Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: ayaka.ishihata@gmail.com.

Yuko Yamauchi (Y)

Department of Infectious Diseases, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: yuuko_yamauchi@tmhp.jp.

Kazuo Yamamoto (K)

Department of Pulmonary Medicine, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: kazu-y@nms.ac.jp.

Hideaki Goto (H)

Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo, 150-0013, Japan. Electronic address: hideaki_gotou@tmhp.jp.

Akifumi Imamura (A)

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18, Honkomagome, Bunkyou-ku, Tokyo, 113-0021, Japan. Electronic address: imamura@kk.iij4u.or.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH